Surabhi Dangi-Garimella, PhD

Federal Perspective on the Biosimilar Influence on Drug Costs

September 14, 2017

Providing an overview on where the healthcare reform debate is headed, Andrew Slavitt, former head of CMS, refined the discussion to highlight the potential for biosimilars to influence the rising costs of drug products.

Industry Regulatory Experts Share Learnings From the Biosimilar Approval Process

September 14, 2017

During a panel on the second day of the 2017 AAM Biosimilars Council Conference, held in Washington DC, regulatory leaders from Pfizer and Sandoz shared their experiences with the development of their biosimilar products: epoetin alfa (Epogen) and etanercept (Erelzi), respectively.